Joint Development and License Agreement Sample Contracts

AzurRx BioPharma, Inc. – ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. JOINT DEVELOPMENT AND LICENSE AGREEMENT (July 13th, 2016)
AzurRx BioPharma, Inc. – ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. JOINT DEVELOPMENT AND LICENSE AGREEMENT (June 16th, 2016)
AzurRx BioPharma, Inc. – ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. JOINT DEVELOPMENT AND LICENSE AGREEMENT (October 16th, 2015)
AzurRx BioPharma, Inc. – CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “****” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. JOINT DEVELOPMENT AND LICENSE AGREEMENT Between Laboratoires Mayoly Spindler SAS and Proteabio Europe SAS (September 8th, 2015)

This Joint Development and License Agreement (the "Agreement") becomes effective as of 1 January 2014 (the "Effective Date"), by and between:

NantKwest, Inc. – JOINT DEVELOPMENT AND LICENSE AGREEMENT (July 27th, 2015)

This Joint Development and License Agreement (this “Agreement”) is made and entered into as of the 18th day of December, 2014 (the “Effective Date”), by and between CONKWEST INCORPORATED, a Delaware corporation with offices at 2533 South Coast Highway 101, Suite 210, Cardiff-By-The-Sea, CA 92007-2133 (“CONKWEST”), and SORRENTO THERAPEUTICS, INC., a Delaware corporation with offices at 6042 Cornerstone Ct. W., San Diego, Ca 92121 (“SRNE”). CONKWEST and SRNE are sometimes referred to herein individually as a “Party” and together as the “Parties.”

Conkwest, Inc. – JOINT DEVELOPMENT AND LICENSE AGREEMENT (June 19th, 2015)

This Joint Development and License Agreement (this “Agreement”) is made and entered into as of the 18th day of December, 2014 (the “Effective Date”), by and between CONKWEST INCORPORATED, a Delaware corporation with offices at 2533 South Coast Highway 101, Suite 210, Cardiff-By-The-Sea, CA 92007-2133 (“CONKWEST”), and SORRENTO THERAPEUTICS, INC., a Delaware corporation with offices at 6042 Cornerstone Ct. W., San Diego, Ca 92121 (“SRNE”). CONKWEST and SRNE are sometimes referred to herein individually as a “Party” and together as the “Parties.”

AMEDICA Corp – JOINT DEVELOPMENT AND LICENSE AGREEMENT (January 29th, 2014)

This Joint Development Agreement (the “Agreement”) entered into as of the 8th day of February, 2010 (the “Effective Date”) is by and between Amedica Corporation, a Delaware corporation with a principal place of business at 1885 West 2100 South, Salt Lake, City, Utah 84119 (“Amedica”) and Orthopaedic Synergy, Inc., a Delaware corporation with a principal place of business at 50 O’Connell Way #10, East Taunton, MA 02718 (“OSI”). Amedica and OSI are each referred to herein as a “Party” and collectively as “Parties”.

AMEDICA Corp – JOINT DEVELOPMENT AND LICENSE AGREEMENT (November 15th, 2013)

This Joint Development Agreement (the “Agreement”) entered into as of the 8th day of February, 2010 (the “Effective Date”) is by and between Amedica Corporation, a Delaware corporation with a principal place of business at 1885 West 2100 South, Salt Lake, City, Utah 84119 (“Amedica”) and Orthopaedic Synergy, Inc., a Delaware corporation with a principal place of business at 50 O’Connell Way #10, East Taunton, MA 02718 (“OSI”). Amedica and OSI are each referred to herein as a “Party” and collectively as “Parties”.

Dyax Corp – TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (August 2nd, 2012)

This FOURTH AMENDMENT (the "Fourth Amendment"), dated as of May 29, 2012 (the "Fourth Amendment Date"), is entered into by and between Dyax Corp. ("Dyax"), and Sigma Tau Rare Diseases S.A. as successor-in-interest to Defiante Farmacêutica S.A. ("STRD").  This Fourth Amendment further amends that certain Joint Development and License Agreement (the "Original Agreement"), dated effective as of June 18, 2010 (the "Effective Date"), as amended by the First Amendment to Joint Development and License Agreement (the "First Amendment”), dated December 21, 2010 (the "First Amendment Date"), the Second Amendment to Joint Development and License Agreement (the "Second Amendment"), dated May 21, 2011 (the "Second Amendment Date") and the Third Amendment to Joint Development and License Agreement (the "Third Amendment"), dated December 26, 2011 (the "Third Amendment Date").  The Original Agreement, as amended by the First Amendment, the Second Amendment and the Third Amendment, is referred to herei

Dyax Corp – Dyax Corp. has requested that portions of this document be accorded confidential treatment pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended. FIFTH AMENDMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (August 2nd, 2012)

This FIFTH AMENDMENT (the "Fifth Amendment"), dated as of June 21, 2012 (the "Fifth Amendment Date"), is entered into by and between Dyax Corp. ("Dyax"), and Sigma Tau Rare Diseases S.A. as successor-in-interest to Defiante Farmacêutica S.A. ("STRD").  This Fifth Amendment further amends that certain Joint Development and License Agreement (the "Original Agreement"), dated effective as of June 18, 2010 (the "Effective Date"), as amended by the First Amendment to Joint Development and License Agreement (the "First Amendment”), dated December 21, 2010 (the "First Amendment Date"), the Second Amendment to Joint Development and License Agreement (the "Second Amendment"), dated May 21, 2011 (the "Second Amendment Date"), the Third Amendment to Joint Development and License Agreement (the "Third Amendment"), dated December 26, 2011 (the "Third Amendment Date") and Fourth Amendment to Joint Development and License Agreement (the "Fourth Amendment"), dated May 29, 2012 (the "Fourth Amendment D

Visualant Inc – Visualant and Sumitomo Precision Products Enter Into Joint Development and License Agreements; Plan to Accelerate Development and Commercialization of SPM Technology (June 4th, 2012)

Seattle, WA. – June 4, 2012, Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology with its Spectral Pattern Matching (“SPM”) technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce the signing of a comprehensive group of agreements with Sumitomo Precision Products Co., Ltd. a Japan corporation.

Dyax Corp – THIRD AMENDMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (March 2nd, 2012)

This THIRD AMENDMENT (the "Third Amendment"), dated as of December 26, 2011 (the "Third Amendment Date"), is entered into by and between Dyax Corp., with effective offices at 300 Technology Square, Cambridge, Massachusetts 02139, U.S.A. ("Dyax"), and DefianteFarmacêutica S.A., with registered offices at Rua da Alfândega, n. 78, 3° andar, 9000-059, Funchal, Madeira, Portugal ("Defiante").  This Third Amendment further amends that certain Joint Development and License Agreement (the "Original Agreement"), dated effective as of June 18, 2010 (the "Effective Date"), as amended by the First Amendment to Joint Development and License Agreement (the "First Amendment”), dated December 21, 2010 (the "First Amendment Date") and the Second Amendment to Joint Development and License Agreement (the "Second Amendment"), dated May 21, 2011 (the "Second Amendment Date").  The Original Agreement, as amended by the First Amendment and the Second Amendment, is referred to herein as the "Amended Agreement

Dyax Corp – SECOND AMENDMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (August 4th, 2011)

This SECOND AMENDMENT (the "Second Amendment"), dated as of May 27, 2011 (the "Second Amendment Date"), is entered into by and between Dyax Corp., with principal offices at 300 Technology Square, Cambridge, Massachusetts 02139, U.S.A. ("Dyax"), and Defiante Farmacêutica S.A., with registered offices at Rua da Alfândega, n. 78, 3° andar, 9000-059, Funchal, Madeira, Portugal ("Defiante").  This Second Amendment further amends that certain Joint Development and License Agreement (the "Original Agreement"), dated effective as of June 18, 2010 (the "Effective Date") as amended by the First Amendment to Joint Development and License Agreement (the "First Amendment”), dated December 21, 2011 (the "First Amendment Date").  The Original Agreement as amended by the First Amendment, is referred to herein as the "Amended Agreement."  All capitalized terms not otherwise defined in this Second Amendment shall be as defined in the Amended Agreement.

Dyax Corp – Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omission. FIRST AMENDMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (March 2nd, 2011)

This FIRST AMENDMENT (the “First Amendment”), dated as of December 21, 2010 (the “Amendment Date”), is entered into by and between Dyax Corp., with principal offices at 300 Technology Square, Cambridge, Massachusetts 02139, U.S.A. (“Dyax”), and Defiante Farmacêutica S.A., with registered offices at Rua da Alfândega, n. 78, 3° andar, 9000-059, Funchal, Madeira, Portugal (“Defiante”).  This First Amendment amends that certain Joint Development and License Agreement (the “Original Agreement”), dated effective as of June 18, 2010 (the “Effective Date”) by and between Dyax and Defiante.  All capitalized terms not otherwise defined in this First Amendment shall be as defined in the Original Agreement.

Dyax Corp – Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omission. JOINT DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN DYAX CORP. AND DEFIANTE FARMACÊUTICA S.A., DATED AS OF JUNE 18, 2010 (August 2nd, 2010)
Verenium Corp – THIRD EXTENSION AGREEMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (July 19th, 2010)

THIS THIRD EXTENSION AGREEMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (this “Third Extension”) is entered into as of July 14, 2010, by and among BP Biofuels North America LLC, a Delaware limited liability company (“BP”), Verenium Biofuels Corporation, a Delaware corporation (“Verenium”), and Galaxy Biofuels LLC, a Delaware limited liability company (“Galaxy”), each of which is referred to herein individually as a “Party,” and collectively as the “Parties.”

Verenium Corp – SECOND EXTENSION AGREEMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (April 1st, 2010)

This SECOND EXTENSION AGREEMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (the “Second Extension”) is entered into as of March 31, 2010, by and among BP Biofuels North America LLC, a Delaware limited liability company (“BP”), Verenium Biofuels Corporation, a Delaware corporation (“Verenium”), and Galaxy Biofuels LLC, a Delaware limited liability company (“Galaxy”), each of which is referred to herein individually as a “Party,” and collectively as the “Parties.”

Verenium Corp – EXTENSION AGREEMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (March 1st, 2010)

This EXTENSION AGREEMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (the “Extension”) is entered into as of February 26, 2010, by and among BP Biofuels North America LLC, a Delaware limited liability company (“BP”), Verenium Biofuels Corporation, a Delaware corporation (“Verenium”), and Galaxy Biofuels LLC, a Delaware limited liability company (“Galaxy”), each of which is referred to herein individually as a “Party,” and collectively as the “Parties.”

Verenium Corp – AMENDMENT NO. 1 TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (February 1st, 2010)

This AMENDMENT NO. 1 TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (the “Amendment”) is entered into as of January 31, 2010, by and among BP Biofuels North America LLC, a Delaware limited liability company (“BP”), Verenium Biofuels Corporation, a Delaware corporation (“Verenium”), and Galaxy Biofuels LLC, a Delaware limited liability company (“Galaxy”), each of which is referred to herein individually as a “Party,” and collectively as the “Parties.”

Palomar Medical Technologies Inc – Fifth Amendment to the September 7, 2004 Joint Development and License Agreement Between Palomar Medical Technologies, Inc. and Johnson & Johnson Consumer Companies, Inc. (the “Agreement”) Whereas, pursuant to the Agreement, the parties are engaged in a collaboration to develop, clinically test and potentially commercialize home-use, light-based devices for (i) reducing or reshaping body fat including cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne; and Whereas, the parties desire to modify certain provisions of the Agreement in order to **; and Whereas (August 5th, 2009)

Whereas, pursuant to the Agreement, the parties are engaged in a collaboration to develop, clinically test and potentially commercialize home-use, light-based devices for (i) reducing or reshaping body fat including cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne; and

Verenium Corp – JOINT DEVELOPMENT AND LICENSE AGREEMENT (November 10th, 2008)
Anadys Pharmaceuticals Inc – Material Terms of the Joint Development and License Agreement between LG Life Sciences and Anadys Pharmaceuticals, Inc. (December 20th, 2007)

On April 18, 2004, we entered into a global joint development and license agreement with LGLS (the “LGLS Agreement”) for the clinical development and commercialization of ANA380 for the treatment of chronic HBV infection. Under the terms of the LGLS Agreement, we were sharing the costs for the global clinical development of ANA380 with LGLS and were granted a license for the future commercialization of ANA380 in the territories of North America, Europe, Japan and the rest of the world other than China, Korea, India and countries in Southeast Asia. In connection with the execution of the LGLS agreement, we paid a licensing fee of $4 million during May 2004 to LGLS. In addition, if the LGLS Agreement had continued and certain development and commercialization objectives had been achieved, we would have had the potential obligation to make additional milestone payments totaling up to $25.5 million. Also under the LGLS Agreement, we would have owed royalties to LGLS on any future product s

Palomar Medical Technologies Inc – Fourth Amendment to the September 7, 2004 Joint Development and License Agreement Between Palomar Medical Technologies, Inc. and Johnson & Johnson Consumer Companies, Inc. (the “Agreement”) Whereas, pursuant to the Agreement, the parties are engaged in a collaboration to develop, clinically test and potentially commercialize home-use, light-based devices for (i) reducing or reshaping body fat including cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne; and Whereas, the parties desire to modify certain provisions of the Agreement in order to **; and Wherea (November 2nd, 2007)

Fourth Amendment to the September 7, 2004 Joint Development and License Agreement Between Palomar Medical Technologies, Inc. and Johnson & Johnson Consumer Companies, Inc. (the “Agreement”)

Palomar Medical Technologies Inc – Third Amendment to the September 7, 2004 Joint Development and License Agreement Between Palomar Medical Technologies, Inc. and Johnson & Johnson Consumer Companies, Inc. (the “Agreement”) Whereas, pursuant to the Agreement, the parties are engaged in a collaboration to develop, clinically test and potentially commercialize home-use, light-based devices for (i) reducing or reshaping body fat including cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne; and Whereas, the parties desire to **. Now, Therefore, in consideration of the foregoing premises, the mu (November 2nd, 2007)

Third Amendment to the September 7, 2004 Joint Development and License Agreement Between Palomar Medical Technologies, Inc. and Johnson & Johnson Consumer Companies, Inc. (the “Agreement”)

Palomar Medical Technologies Inc – Second Amendment to the September 7, 2004 Joint Development and License Agreement Between Palomar MedicalTechnologies, Inc. and Johnson & Johnson Consumer Companies, Inc. (the “Agreement”) Whereas, pursuant to the Agreement, the parties are engaged in a collaboration to develop, clinically test and potentially commercialize home-use, light-based devices for (i) reducing or reshaping body fat including cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne; and Whereas, the parties desire to modify certain provisions of the Agreement in order to **. Now, Theref (May 8th, 2007)

Second Amendment to the September 7, 2004 Joint Development and License Agreement Between Palomar MedicalTechnologies, Inc. and Johnson & Johnson Consumer Companies, Inc. (the “Agreement”)

Palomar Medical Technologies Inc – First Amendment to the September 7, 2004 Joint Development and License Agreement Between Palomar MedicalTechnologies, Inc. and Johnson & Johnson Consumer Companies, Inc. (the “Agreement”) Whereas, pursuant to the Agreement, the parties are engaged in a collaboration to develop, clinically test and potentially commercialize home-use, light-based devices for (i) reducing or reshaping body fat including cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne; and Whereas, the parties desire to modify certain provisions of the Agreement in order to **. Now, Therefo (August 8th, 2006)

First Amendment to the September 7, 2004 Joint Development and License Agreement Between Palomar MedicalTechnologies, Inc. and Johnson & Johnson Consumer Companies, Inc. (the “Agreement”)

Anadys Pharmaceuticals Inc – i ARTICLE 8 Indemnification.................................................... ............. 27 8.1 Indemnification By Anadys........................................ 27 8.2 Indemnification By LGLS.......................................... 27 ARTICLE 9 Confidentiality.... ............................................................. 28 9.1 General Rule..................................................... 28 9.2 Exclusions....................................................... 28 9.3 Survival......................................................... 28 9.4 Governmental Filings..................... (August 16th, 2004)
Sage Inc/Ca – JOINT DEVELOPMENT AND LICENSE AGREEMENT (October 28th, 1999)
Sage Inc/Ca – JOINT DEVELOPMENT AND LICENSE AGREEMENT (October 12th, 1999)
Sage Inc/Ca – JOINT DEVELOPMENT AND LICENSE AGREEMENT (August 30th, 1999)
Mips Technologies Inc – JOINT DEVELOPMENT AND LICENSE AGREEMENT (March 11th, 1999)
Mips Technologies Inc – JOINT DEVELOPMENT AND LICENSE AGREEMENT (March 11th, 1999)
Mips Technologies Inc – JOINT DEVELOPMENT AND LICENSE AGREEMENT (March 11th, 1999)
Mips Technologies Inc – JOINT DEVELOPMENT AND LICENSE AGREEMENT (March 11th, 1999)
Mips Technologies Inc – JOINT DEVELOPMENT AND LICENSE AGREEMENT (February 26th, 1999)